NIH Highlighted Topic: Supporting Research Using the Resources from the Osteoarthritis Initiative (OAI)
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals that leverage the Osteoarthritis Initiative (OAI) database, clinical datasets, biospecimens, and imaging resources to advance osteoarthritis (OA) research and translational healthcare innovation. This highlighted topic is designed to expand the use of the OAI resource across the broader scientific and technology community, particularly through multidisciplinary and data-driven research approaches.
NIH is particularly interested in projects focused on novel analyses of osteoarthritis epidemiology and disease progression, integration of imaging and clinical data, biomarker discovery, predictive modeling, and the application of AI, machine learning, and advanced data science techniques to musculoskeletal health. Companies developing digital health platforms, AI-enabled diagnostics, medical imaging analytics, predictive healthcare software, biomarkers, wearable health technologies, or data integration tools may be strong candidates for funding.
Areas of interest include automated MRI and X-ray analysis tools, multimodal predictive modeling, disease trajectory analysis, biospecimen analytics, intervention effectiveness modeling, and real-world evidence studies using electronic health records (EHRs). NIH is also encouraging research addressing women’s musculoskeletal health, osteoarthritis progression during menopause, and sex-linked OA risk factors.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for follow-on and commercialization funding depending on project scope and impact.
This highlighted topic is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), and the Office of Research on Women’s Health (ORWH), all of which are seeking high-impact innovations that improve osteoarthritis diagnosis, monitoring, prevention, treatment, and long-term patient outcomes.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of technologies, software platforms, diagnostics, and data-driven solutions related to osteoarthritis research and musculoskeletal health.
Eligible activities may include:
AI and machine learning tools for osteoarthritis diagnosis and prediction
Automated MRI and X-ray image analysis platforms
Predictive analytics for OA progression and intervention outcomes
Biomarker discovery and biospecimen analysis technologies
Multimodal data integration platforms combining imaging, genetics, and clinical data
Computational modeling of osteoarthritis disease progression
Real-world evidence platforms leveraging EHR and longitudinal patient data
Clinical decision support software for musculoskeletal disorders
Digital health and remote patient monitoring technologies
Wearable devices for mobility, gait, and musculoskeletal tracking
Data science tools for population health and epidemiological analysis
Women’s health technologies focused on OA risk and resilience factors
Research platforms supporting longitudinal cohort analysis
Advanced statistical and bioinformatics tools for musculoskeletal research
Translational studies supporting diagnostics and therapeutic discovery
Prototype development, validation studies, and regulatory preparation
Commercialization planning and market validation activities
Funding may also support personnel, clinical data analysis, cloud infrastructure, software development, imaging analytics, laboratory testing, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a commercially viable healthcare or medtech solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
